The presence of both ACE D and AT(1)-R C(1166) alleles in genotyped HCM patients was associated with significantly lower ejection fraction (48% vs 58%, P<0.05) and larger LV end-systolic dimension.
Observational (n=126)
Do RAS polymorphisms (ACE D and AT1-R C1166 alleles) affect left ventricular function and morphology in patients with genotyped hypertrophic cardiomyopathy?
The presence of both the ACE D and AT1-R C1166 alleles is associated with left ventricular dilation and systolic dysfunction in patients with genotyped hypertrophic cardiomyopathy.
Absolute Event Rate: 48% vs 58%
p-value: p=<0.05
BACKGROUND: Although the renin-angiotensin system (RAS) can affect the development of left ventricular (LV) hypertrophy, few data exist regarding the relationships between RAS polymorphisms and alteration of LV function. The effect of RAS polymorphisms on LV function in genotyped hypertrophic cardiomyopathy (HCM) was examined in the present study. METHODS AND RESULTS: The study group comprised 126 carriers with sarcomere gene mutations from 49 HCM families (64 males, mean age 51±21 years). LV morphology and function were evaluated by echocardiography. In angiotensin-converting enzyme (ACE) insertion/deletion (I/D), the D allele (n=81) exhibited significantly larger LV end-systolic dimension (LVDs) (32±11mm) and lower ejection fraction (56±15%) than those with the II genotype (28±7mm and 62±12%, respectively, P<0.05; n=45). Although angiotensin II type 1 receptor (AT(1)-R) A/C(1166) polymorphism did not affect echocardiographic parameters, the presence of the ACE D allele with the AT(1)-R C(1166) allele (n=9) was associated with larger LVDs (37±17mm) and lower ejection fraction (48±20%) compared with other genotypes (30±9mm and 58±14%, respectively, P<0.05; n=117). Under these conditions, severe LV hypertrophy was frequently associated with LV wall thinning. CONCLUSIONS: The presence of both the ACE D and AT(1)-R C(1166) allele is associated with LV dilation with systolic dysfunction in genotyped HCM. In addition to the severity of LV hypertrophy, screening for these RAS polymorphisms could contribute to further risk stratification of patients with HCM, although other genetic polymorphisms should be further examined.
Funada et al. (Fri,) conducted a observational in Hypertrophic cardiomyopathy (n=126). ACE D and AT(1)-R C(1166) alleles vs. Other genotypes was evaluated on Ejection fraction (p=<0.05). The presence of both ACE D and AT(1)-R C(1166) alleles in genotyped HCM patients was associated with significantly lower ejection fraction (48% vs 58%, P<0.05) and larger LV end-systolic dimension.